Okklo Life Sciences

Company
Technology
Programs
Partnering
News
Contact
- Where to meet us
- Disclaimer

Via our unique expertise and network we can design novel cyclodextrins for a wide variety of therapeutic areas

Our vision is to be the leading biotech providing cyclodextrin-based therapeutics to improve the life of patients.

Okklo Life Sciences: custom design and development of therapeutic cyclodextrins

Okklo Life Sciences

Novel therapeutic solutions using cyclodextrin-based technologies

Drug Discovery Today

Milestone moment for the region’s life science sector as construction on No. 1 Birmingham Health Innovation Campus gets underway. 10/13/2021
AstraZeneca analysed rare variant contribution to human disease 09/22/2021
Potential new drug for incurable vascular dementia 09/16/2021
Touchlight extends funding round to US$125M as demand for its dbDNA™ grows rapidly 09/16/2021
Medicines Manufacturing Innovation Centre set to Transform UK Pharma 08/23/2021

Follow us on:

Recent Okklo News

Okklo’s hematology asset will be further developed by Alveron Pharma 05/16/2019
Okklo and SolAeroMed partner to develop cyclodextrins for cystic fibrosis treatment 06/27/2017
Okklo Life Sciences B.V. and Sanquin sign commercialization agreement to enter IND enabling studies and clinical development. 01/10/2017
Okklo receives RedMedTech Ventures funding and extends collaboration with Sanquin 05/15/2016

Company
Technology
Programs
Partnering
News
Contact

Copyright © 2016 | Okklo Life Sciences | All Rights Reserved